These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37535913)

  • 1. Progress in the Treatment of Metabolic-Related Fatty Liver Disease.
    Zhang B; Feng Y; Lu J
    Altern Ther Health Med; 2023 Oct; 29(7):86-93. PubMed ID: 37535913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
    Kjær MB; George J; Kazankov K; Grønbæk H
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD).
    Rong L; Zou J; Ran W; Qi X; Chen Y; Cui H; Guo J
    Front Endocrinol (Lausanne); 2022; 13():1087260. PubMed ID: 36726464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAFLD: Mechanisms, Treatments, and Biomarkers.
    Nassir F
    Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the role of nucleotide methylation in metabolic-associated fatty liver disease.
    Zhang N; Tian X; Yan T; Wang H; Zhang D; Lin C; Liu Q; Jiang S
    Front Immunol; 2023; 14():1148722. PubMed ID: 37020540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
    Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
    Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review.
    Lu R; Liu Y; Hong T
    Diabetes Obes Metab; 2023 Apr; 25 Suppl 1():13-26. PubMed ID: 36775938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How far are we from an approved drug for nonalcoholic steatohepatitis?
    Méndez-Sánchez N; Pal SC; Córdova-Gallardo J
    Expert Opin Pharmacother; 2023 Jun; 24(9):1021-1038. PubMed ID: 37092896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infections at the nexus of metabolic-associated fatty liver disease.
    Boeckmans J; Rombaut M; Demuyser T; Declerck B; Piérard D; Rogiers V; De Kock J; Waumans L; Magerman K; Cartuyvels R; Rummens JL; Rodrigues RM; Vanhaecke T
    Arch Toxicol; 2021 Jul; 95(7):2235-2253. PubMed ID: 34027561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia.
    Keating SE; Sabag A; Hallsworth K; Hickman IJ; Macdonald GA; Stine JG; George J; Johnson NA
    Sports Med; 2023 Dec; 53(12):2347-2371. PubMed ID: 37695493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.
    Barchetta I; Cimini FA; Cavallo MG
    Nutrients; 2020 Oct; 12(11):. PubMed ID: 33126575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions.
    Alshehade S; Alshawsh MA; Murugaiyah V; Asif M; Alshehade O; Almoustafa H; Al Zarzour RH
    Life Sci; 2022 Sep; 305():120732. PubMed ID: 35760093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
    Kuchay MS; Choudhary NS; Mishra SK; Misra A
    Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment.
    Sangro P; de la Torre Aláez M; Sangro B; D'Avola D
    J Physiol Biochem; 2023 Nov; 79(4):869-879. PubMed ID: 36976456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease.
    Hartl L; Elias J; Prager G; Reiberger T; Unger LW
    World J Gastroenterol; 2021 May; 27(19):2281-2298. PubMed ID: 34040322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical approaches to non-alcoholic fatty liver disease.
    Schwenger KJ; Allard JP
    World J Gastroenterol; 2014 Feb; 20(7):1712-23. PubMed ID: 24587650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAFLD and CKD: An Updated Narrative Review.
    Mantovani A; Lombardi R; Cattazzo F; Zusi C; Cappelli D; Dalbeni A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiological mechanisms underlying MAFLD.
    Kuchay MS; Choudhary NS; Mishra SK
    Diabetes Metab Syndr; 2020; 14(6):1875-1887. PubMed ID: 32998095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.